US 11,655,287 B2
Use of regulatory T cell-specific surface protein LRIG-1
Sang-kyou Lee, Seoul (KR)
Assigned to Good T Cells, Inc., Seoul (KR)
Appl. No. 14/427,421
Filed by Sang-kyou Lee, Seoul (KR)
PCT Filed Jan. 20, 2012, PCT No. PCT/KR2012/000532
§ 371(c)(1), (2), (4) Date Aug. 10, 2015,
PCT Pub. No. WO2012/102527, PCT Pub. Date Aug. 2, 2012.
Claims priority of application No. 10-2011-0007022 (KR), filed on Jan. 24, 2011.
Prior Publication US 2015/0239964 A1, Aug. 27, 2015
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); C12N 15/113 (2010.01); G01N 33/68 (2006.01); G01N 33/94 (2006.01); G01N 33/50 (2006.01); A61K 35/17 (2015.01); C07K 14/47 (2006.01); C12Q 1/6876 (2018.01); A61K 38/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 35/17 (2013.01); C07K 14/47 (2013.01); C12N 15/113 (2013.01); C12N 15/1138 (2013.01); C12Q 1/6876 (2013.01); G01N 33/505 (2013.01); G01N 33/5023 (2013.01); G01N 33/6854 (2013.01); G01N 33/6872 (2013.01); G01N 33/9493 (2013.01); A61K 38/00 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/17 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01)] 6 Claims
 
1. A method for reducing activity of regulatory CD4+CD25high T cells (Treg) against activated T cells, comprising administering an agent to regulatory CD4+CD25high T cells, wherein the agent is an antisense oligonucleotide having a sequence complementary to a nucleotide sequence as set forth in SEQ ID NO: 12 or a small interfering RNA (siRNA) molecule having a sequence complementary to a nucleotide sequence as set forth in SEQ ID NO: 12 that reduces expression levels of Lrig1 protein by the CD4+CD25high regulatory T cells and inhibits proliferation of the CD4+CD25high regulatory T cells.